Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27866402 | 1.00 | APP (0.58) | APPATMHCAR2ALOX5ESR1 | |
| SCHEMBL22961507 | 0.85 | APP (0.58) | APPATMHCAR2ALOX5ESR1 | |
| SCHEMBL563576 | 0.84 | CA12 (0.58) | APPHCAR2ALOX5MAPTRAB9A | |
| SCHEMBL563578 | 0.84 | CA12 (0.58) | APPHCAR2ALOX5MAPTRAB9A | |
| SCHEMBL24516291 | 0.84 | APP (0.57) | APPATMHCAR2ALOX5ESR1 | |
| SCHEMBL20033498 | 0.83 | PADI4 (0.45) | APPALOX5LMNAMAPTTDP1 | |
| SCHEMBL4621254 | 0.83 | L3MBTL1 (0.57) | APPATMLMNAMAPTRAB9A | |
| SCHEMBL14958898 | 0.83 | APP (0.56) | APPATMHCAR2ALOX5ESR1 | |
| SCHEMBL4621246 | 0.83 | L3MBTL1 (0.57) | APPATMLMNAMAPTRAB9A | |
| SCHEMBL14960207 | 0.82 | APP (0.55) | APPATMHCAR2ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | APP 2170/4885ATM 25/4885HCAR2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.